Invention:
This innovation is a method and composition for treating, preventing, or delaying the progression of neurodegenerative diseases using cell type-specific gene therapy. The therapy is delivered to human or veterinary subjects using an adeno-associated virus (AAV) vector that carries the peroxisome proliferator-activated receptor alpha (PPARA) gene. The focus of this therapeutic is on the role of astrocytes, a type of cell in the brain that supports and interacts with neurons. The researchers have developed an AAV vector that specifically targets and upregulates the expression of the mouse Ppara gene in astrocytes, while not affecting other cell types in the brain. By increasing the activity of fatty acid (FA) degradation in astrocytes, the treatment aims to restore lipid balance and alleviate the detrimental effects of lipid dysregulation observed in neurodegenerative diseases. In preclinical studies using a mouse model of AD, this treatment has shown promising results, including reduced beta-amyloid plaque accumulation, improved synaptic plasticity, and cognitive function. The novelty of this technology lies in the combination of specific AAV vector serotypes, a promoter with high astrocyte specificity, and the target gene PPARA, which together provide an efficient and targeted approach to treating neurodegenerative diseases characterized by lipid dysregulation.
Background:
Current treatment approaches for neurodegenerative diseases include pharmaceutical interventions, such as cholinesterase inhibitors and NMDA receptor antagonists, which provide symptomatic relief but do not address the underlying factor of lipid dysregulation. Other approaches, such as gene therapies, have been explored, but they often lack cell type specificity, leading to unintended effects and potential side effects. This lack of cell type-specific targeting and intervention leads to limited effectiveness and suboptimal outcomes in halting disease progression and improving cognitive function. By specifically targeting and upregulating PPARA expression in astrocytes, this treatment directly addresses the impaired fatty acid degradation in these cells, providing a precise and efficient way to restore lipid balance and mitigate the detrimental effects on neuronal health and cognitive function.
Applications:
- Treatment for neurodegenerative diseases
- Alzheimer's Disease
- Parkinson’s Disease
Advantages:
- Cell type-specific targeted treatment
- Mitigates detrimental effects on neuronal health
- Improved synaptic plasticity
- Reduced beta-amyloid plaque accumulation
- Improved cognitive function
- Mouse model data with promising results
